Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
04:05pm, Thursday, 01'st May 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
07:30am, Thursday, 03'rd Apr 2025
NEW HAVEN, Conn. , April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
06:47pm, Tuesday, 18'th Mar 2025
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini -
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
04:05pm, Tuesday, 18'th Mar 2025
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
04:05pm, Tuesday, 11'th Mar 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
11:30am, Monday, 10'th Mar 2025
On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).
Haduvio met the primary endpoint with a statistically-significant reduction (p
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
07:30am, Thursday, 27'th Feb 2025
NEW HAVEN, Conn. , Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
07:30am, Thursday, 30'th Jan 2025
NEW HAVEN, Conn. , Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
01:00pm, Wednesday, 08'th Jan 2025
Trevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January and topline results continue to be expected in the first quarter of 2025 Approximately 80% of enrollm
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
07:36am, Monday, 16'th Dec 2024
NEW HAVEN, Conn. , Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphin
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
09:47am, Thursday, 12'th Dec 2024
On Thursday, Trevi Therapeutics, Inc. TRVI announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patie
